(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 6.38% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Johnson & Johnson's revenue in 2026 is $97,929,000,000.On average, 26 Wall Street analysts forecast JNJ's revenue for 2026 to be $246,390,442,455,877, with the lowest JNJ revenue forecast at $238,028,094,324,287, and the highest JNJ revenue forecast at $257,945,906,228,492. On average, 26 Wall Street analysts forecast JNJ's revenue for 2027 to be $264,394,794,874,064, with the lowest JNJ revenue forecast at $252,569,422,458,585, and the highest JNJ revenue forecast at $280,514,606,589,397.
In 2028, JNJ is forecast to generate $284,565,646,130,954 in revenue, with the lowest revenue forecast at $269,313,397,910,541 and the highest revenue forecast at $303,271,279,040,868.